Epidemiology of oral contraceptive related thrombosis

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 1-6

  Bloemenkamp, K W M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CHLORMADINONE; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; DYDROGESTERONE; ETHINYLESTRADIOL; ETHYNODIOLACTONE; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; NORGESTREL; NORGESTRIENONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; UNCLASSIFIED DRUG;

ANTITHROMBIN DEFICIENCY; ARTERY DISEASE; ARTERY THROMBOSIS; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DISEASE CARRIER; DISEASE PREDISPOSITION; FERTILIZATION IN VITRO; GENE MUTATION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; ORAL CONTRACEPTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM;

EID: 12544257022     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.11.015     Document Type: Conference Paper

References (61)

1. United Nations Department for Economic and Social Information and Policy Analysis Popula-tion Division. Levels and trends of contraceptive use as assessed in 1994. New York, United Nations; 1996.
2. Robinson GE. Low-dose combined oral contraceptives. Br J Obstet Gynaecol 1994;101:1036-42.
3. Fotherby K, Caldwell ADS. New progestogens in oral contraception. Contraception 1994;49:1-32.
4. Diczfalusy E. The contraceptive revolution: an era of scientific and social development. Canrnforth, UK: Parthenon Publishing; 1997.
5. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. Chapter 22 Oral contraception: 715-763. Fifth edition. Baltimore, USA: Williams and Wilkins; 1994.
6. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Thrombophilias and gynaecology. Best Pract Res Clin Obstet Gynaecol 2003;17(3):509-28.
7. Hannaford P. The collection and interpretation of epidemiological data about the cardiovascular risks associated with the use of steroid contraceptives. Contraception 1998;57(3):137-42.
8. Cardiovascular disease and steroid hormone contraception. Report of a WHO scientific group. Geneva, World Health Organization, 1998 (WHO Technical Report Series, No. 877).
9. Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel- containing oral contraceptives: a review. Am J of Obstet Gynecol 1998;179:S51-61.
10. Rosing J, Middeldorp S, Curvers J, Thomassen MCLGD, Nicolaes GAF, Meijers JCM, Bouma BN, Büller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999;354:2036-40.
11. Middeldorp S, Meijers JCM, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of levonorgestrel and desogestrel containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000;84:4-8.
12. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004 (Feb 1);103(3):927-33. Epub 2003 Oct 09.
13. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 2002;87(2):199-205.
14. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Buller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84(1):15-21.
15. Meijers JCM, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Rosing J, Büller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an ehanced factor XI-independent down regulation of fibrinolysis; a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000;84:9-14.
16. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 2002;13(5):373-81.
17. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
18. Jordan WM. Pulmonary embolism. Lancet 1961;i:1146.
19. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35.
20. Cardiovascular disease and steroid hormone contraception. Report of a WHO scientific group. Geneva, World Health Organization, 1998 (WHO Technical Report Series, No. 877).
21. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
22. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999;159(1):65-70.
23. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
24. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
25. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-8.
26. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton JR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
27. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6.
28. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sørensen HT, Baech J, Gregersen H. Third-generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998;79:23-31.
29. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A casecontrol study. Contraception 1998;57:291-301.
30. Lewis MA, MacRae KD, Kühl-Habich D, Bruppacher R, Heinemann LAJ, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-9.
31. Herings RMC, Urquhart J, Leufkens HGM. Noncausal explanations for the increased risk of venous thromboembolism among users of third-generation oral contraceptives. Pharmacoepidem drug safety 1996;5:S1-119.
32. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127-8.
33. Mellemkjaer L, Sørensen HT, Dreyer L, Olsen J, Olsen JH. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95. BMJ 1999;319:820-1.
34. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323(7305):131-4.
35. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001;64(2):125-33.
36. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. Third edition WHO 2004. http://www. who.int/reproductive-health/publications/MEC_3/index.
37. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160(1):49-52.
38. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
39. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sørensen HT, Baech J, Gregersen H. Thirdgeneration oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998;79:23-31.
40. Hellgren M, Svenson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-3.
41. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
42. Simioni P, Sanson BJ, Prandoni, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.
43. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994;71:548-52.
44. Girolami A, Simioni P, Girolami B, Zanardi S. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. Blood Coagul Fibrinolysis 1991;2:673-8.
45. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999;82(3):1024-7.
46. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
47. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19(3):700-3.
48. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, Thomas S, Mann R. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999;318:1579-83.
49. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FR. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93.
50. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997;56(3):129-40.
51. Sidney S, Siscovick DS, Petitti DB, Schwartz SM, Quesenberry CP, Psaty BM, Raghunathan TE, Kelaghan J, Koepsell TD. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998;98(11):1058-63.
52. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-9.
53. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR, Algra A. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002;33(5):1202-8.
54. Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher R. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of YoungWomen. Contraception 1998;57(1):29-37.
55. Schwartz SM, Petitti DB, Siscovick DS, Longstreth WT Jr, Sidney S, Raghunathan TE, Quesenberry CP Jr, Kelaghan J. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998;29(11):2277-84.
56. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:498-505.
57. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57(3):211-30.
58. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90(5):1747-50.
59. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89(8):2817-21.
60. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97(11):1037-41.
61. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003;107(8):1117-22.